Growth Potential

The market for MS therapeutics is mainly split between five pharmaceuticals (Avonex, Rebif, Betaferon/Betaseron, Copaxone and Tysabri). Tysabri was reintroduced as monotherapy treatment for relapsing forms of multiple sclerosis in 2006.

Although these are pharmaceuticals that can slow the progression of the disease in some patients, the need for new and effective pharmaceuticals in MS is substantial. All of the pharmaceuticals used for the treatment of MS on the market today require frequent injections causing serious discomfort for patients. Introduction of an efficacious oral treatment would undoubtedly fuel further growth.

Another important growth factor is the trend towards early treatment, in order to slow disease progression, resulting in larger treated patient populations..